| ［1］Mizoguchi A, Mizoguchi E, Smith RN, et al. Suppressive role of B cells in chronic colitis of T cell receptor alpha mutant mice［J］. J Exp Med, 1997, 186(10): 1749-1756.
［2］Iwata Y, Matsushita T, Horikawa M, et al. Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells［J］. Blood, 2011, 117(2): 530-541.
［3］Gao N, Dresel J, Eckstein V, et al. Impaired suppressive capacity of activation-induced regulatory B cells in systemic lupus erythematosus［J］. Arth Rheumatol, 2014, 66(10): 2849-2861.
［4］Khoder A,Sarvaria A,Alsuliman A,et al.Regulatory B cells are enriched within the IgM memory and transitional subsets in healthy donors but are deficient in chronic GVHD［J］.Blood,2014,124(13):2034-2045.
［5］Barros MM, Blajchman MA, Bordin JO. Autoimmune hemolytic anemia: recent progress in understanding the immunobiology and the treatment［J］. Trans Med Rev, 2010, 24(3) : 195-210.
［6］Wilma B, Francesco Z, Anna Z, et al. Low-dose rituximab in adult patients with idiopathic autoimmune hemolytic anemia: clinical efficacy and biologic studies ［J］. Blood, 2012, 119: 3691-3697.
［7］Hall AM, Ward FJ, Vickers MA, et al. Interleukin-10-mediated regulatory T-cell responses to epitopes on a human red blood cell autoantigen［J］. Blood, 2002, 100: 4529-4536.
［8］Penalver FJ, Alvarez-Larran A, Diez-Martin JL, et a1. Rituximab is an effective and safe therapeutic alternative in adults with refractory and severe autoimmune hemolyticanemia［J］. Ann Hematol, 2010, 89(11): 1073-1080．
［9］Goetz M,Atreya R,Ghalibafian M,et al.Exacerbation of ulcerative colitis after rituximab salvage therapy［J］.Inflamm Bowel Dis,2007,13(11):1365-1368.
［10］徐伟来，陈小会，倪万茂，等. 原发免疫性血小板减少症患者外周血调节性B细胞水平及其与病程和疗效关系的初步研究［J］. 中华血液学杂志, 2013, 34(12): 1055-1056. |
